Paivi A.
- Country
- Finland
- Department
- Syopatautien poliklinikka
Research Overview
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
- Phase 3 Randomized Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in Triple-Negative Breast Cancer Post-Neoadjuvant Therapy
- Phase III Randomized Study of Trastuzumab, Pertuzumab, and Docetaxel in HER2-Positive Early Breast Cancer
Data & Insights
Has run more than one trial at 180 of 418 partner sites.
Specializations
Advanced Breast Cancer Treatment
The investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular emphasis on advanced and metastatic cases. Their research encompasses innovative therapeutic approaches for patients who have progressed after initial treatment.
- Metastatic breast cancer management
- Hormone receptor-positive disease
- Treatment resistance strategies
HER2-Positive Breast Cancer
Focused on developing treatment strategies for HER2-positive breast cancer, including both early-stage and advanced disease. The investigator studies targeted therapeutic combinations incorporating trastuzumab and pertuzumab.
- Early-stage breast cancer treatment
- Advanced HER2+ disease management
- Targeted therapy combinations
Endocrine Therapy Innovation
The investigator explores novel approaches in endocrine therapy resistance, particularly studying new therapeutic agents like giredestrant and their comparison with established treatments such as fulvestrant.
- Endocrine therapy resistance
- Novel therapeutic agents
- ESR1 mutation studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.